This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Pharma Stocks With 100% Buy Ratings

NEW YORK ( TheStreet) -- The following 10 global pharmaceutical stocks will likely benefit from the expanding global pharmaceutical markets, which are poised to grow at 5%-7% in 2011 to $880 billion, according to IMS Health. 17 Pharmemerging markets, including China and India, are forecast to grow at 15%-17% in 2011 to $180 billion, faster than the global markets.

Analysts give these 10 stocks a 100% buy ratings. In comparison, pharma giants Johnson & Johnson (JNJ), Pfizer (PFE), Merck (MRK), Abbott Laboratories (ABT), Bristol Myers Squibb (BMY) and Eli Lilly (LLY) have buy ratings in the range of 8.3%-71.4%.

In addition, analysts expect these 10 stocks to outperform their peers and broader markets, based on the upside implied from their respective 12-month price targets. These stocks have an implied upside potential of 25%-147% with a mean upside value of around 91%.

With five analysts covering the stock, Aegerion Pharmaceuticals (AEGR) has 100% buy ratings, however, we have not included the stock in our discussion since analysts expect the stock to have an upside of only 12%, much lower than the 10 stocks listed here. The other stocks that do not find a place here are AVANIR Pharmaceuticals (AVNR), Somaxon Pharmaceuticals (SOMX), Biostar Pharmaceuticals (BSPM), Threshold Pharmaceuticals (THLD), EpiCept (EPCT), Ventrus Biosciences (VTUS) and Repros Therapeutics (RPRX), even though they are expected to have triple-digit upsides because only a few analysts cover these stocks.

The stocks are stacked in an ascending order based on the number of analysts covering each stock and, in case of a tie-up, by implied percentage upside.

1 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
PATH $0.00 0.00%
ATHX $1.29 0.00%
BDSI $9.26 0.00%
CPHI $0.38 0.00%
MNOV $4.09 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs